ArticleRadiation oncology (London, England)2012

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.

Colin Brooks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.